Journal ArticleDOI
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
Marshall R. Posner,Diane Hershock,Cesar R. Blajman,Elizabeth Mickiewicz,Eric Winquist,Vera Gorbounova,Sergei Tjulandin,Dong M. Shin,Kevin J. Cullen,Thomas J. Ervin,Barbara A. Murphy,Luis E. Raez,Roger B. Cohen,Monica Spaulding,Roy B. Tishler,Berta Roth,Rosana del Carmen Viroglio,Varagur Venkatesan,Ilya Romanov,Sanjiv S. Agarwala,K. William Harter,Matthew Dugan,Anthony J. Cmelak,Arnold M. Markoe,Paul W. Read,Lynn Steinbrenner,A. Dimitrios Colevas,Charles M. Norris,Robert I. Haddad +28 more
TLDR
Patients with squamous-cell carcinoma of the head and neck who received docetaxel plus cisplatin and fluorouracil induction chemotherapy plus chemoradiotherapy had a significantly longer survival than did patients who received cisPlatin and fluoride induction chemotherapyplus cheMoradiotherapy.Abstract:
Background A randomized phase 3 trial of the treatment of squamous-cell carcinoma of the head and neck compared induction chemotherapy with docetaxel plus cisplatin and fluorouracil (TPF) with cisplatin and fluorouracil (PF), followed by chemoradiotherapy. Methods We randomly assigned 501 patients (all of whom had stage III or IV disease with no distant metastases and tumors considered to be unresectable or were candidates for organ preservation) to receive either TPF or PF induction chemotherapy, followed by chemoradiotherapy with weekly carboplatin therapy and radiotherapy for 5 days per week. The primary end point was overall survival. Results With a minimum of 2 years of follow-up (≥3 years for 69% of patients), significantly more patients survived in the TPF group than in the PF group (hazard ratio for death, 0.70; P=0.006). Estimates of overall survival at 3 years were 62% in the TPF group and 48% in the PF group; the median overall survival was 71 months and 30 months, respectively (P=0.006). There...read more
Citations
More filters
Journal ArticleDOI
Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients
TL;DR: In this paper, the authors conducted an individual patient data (IPD) meta-analysis, which showed that chemotherapy improved survival in patients curatively treated for non-metastatic head and neck squamous cell carcinoma (HNSCC), with a higher benefit with concomitant chemotherapy.
Journal ArticleDOI
Head and neck cancer
TL;DR: The epidemiology, molecular pathogenesis, diagnosis and staging, and the latest multimodal management of squamous cell carcinoma of the head and neck are reviewed.
Journal ArticleDOI
Clinical practice guidelines in oncology
William J. Gradishar,Benjamin O. Anderson,Ron Balassanian,Sarah L. Blair,Harold J. Burstein,Amy E. Cyr,Anthony D. Elias,William B. Farrar,Andres Forero,Sharon H. Giordano,Matthew P. Goetz,Lori J. Goldstein,Steven J. Isakoff,Janice A. Lyons,P. Kelly Marcom,Ingrid A. Mayer,Beryl McCormick,Meena S. Moran,Ruth O'Regan,Sameer A. Patel,Lori J. Pierce,Elizabeth C. Reed,Kilian E. Salerno,Lee S. Schwartzberg,Amy Sitapati,Karen L. Smith,Mary Lou Smith,Hatem Soliman,George Somlo,Melinda L. Telli,John H. Ward,Rashmi Kumar,Dorothy A. Shead +32 more
TL;DR: This manuscript focuses on the NCCN Guidelines Panel recommendations for the workup, primary treatment, risk reduction strategies, and surveillance specific to DCIS.
Journal ArticleDOI
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Jan B. Vermorken,Eva Remenar,Carla M.L. van Herpen,Thierry Gorlia,Ricard Mesia,M. Degardin,John S. Stewart,Svetislav Jelic,Jan Betka,Joachim H. Preiss,Danielle Van den Weyngaert,Ahmad Awada,Didier Cupissol,Heinz Roland Kienzer,Augustin Rey,Isabelle Desaunois,Jacques Bernier,Jean-Louis Lefebvre +17 more
TL;DR: Induction chemotherapy with the addition of docetaxel significantly improved progression-free and overall survival in patients with unresectable squamous-cell carcinoma of the head and neck.
Journal ArticleDOI
Head and neck squamous cell carcinoma
Daniel Johnson,Barbara Burtness,C. René Leemans,Vivian Wai Yan Lui,Julie E. Bauman,Jennifer R. Grandis +5 more
TL;DR: This Primer provides an overview of the epidemiology, pathogenesis and treatment of HNSCCs of different aetiologies and the effects of the cancer and its treatment on patient quality of life.
References
More filters
Journal ArticleDOI
Cancer statistics, 2006.
Ahmedin Jemal,Rebecca L. Siegel,Elizabeth Ward,Taylor Murray,Jiaquan Xu,Carol Smigal,Michael J. Thun +6 more
TL;DR: The American Cancer Society estimated the number of new cancer cases and deaths expected in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival based on incidence data from the National Cancer Institute and mortality data from National Center for Health Statistics as discussed by the authors.
Journal ArticleDOI
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
James A. Bonner,Paul M. Harari,Jordi Giralt,Nozar Azarnia,Dong M. Shin,Roger B. Cohen,Christopher U. Jones,Ranjan Sur,David Raben,Jacek Jassem,Roger Ove,Merrill S. Kies,José Baselga,Hagop Youssoufian,Nadia Amellal,Eric K. Rowinsky,Eric K. Rowinsky,K. Kian Ang +17 more
TL;DR: Treatment of locoregionally advanced head and neck cancer with concomitant high-dose radiotherapy plus cetuximab improves locoreGional control and reduces mortality without increasing the common toxic effects associated with radiotherapy to the head andneck.
Journal ArticleDOI
Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer
Arlene A. Forastiere,Helmuth Goepfert,Moshe H. Maor,Thomas F. Pajak,Randal S. Weber,William H. Morrison,Bonnie S. Glisson,Andy Trotti,John A. Ridge,C. Chao,Glen Peters,Ding Jen Lee,Andrea Leaf,John F. Ensley,Jay S. Cooper +14 more
TL;DR: In patients with laryngeal cancer, radiotherapy with concurrent administration of cisplatin is superior to induction chemotherapy followed by radiotherapy or radiotherapy alone for larynGEal preservation and locoregional control.
Journal ArticleDOI
Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck.
Jay S. Cooper,Thomas F. Pajak,Arlene A. Forastiere,John R. Jacobs,Bruce H. Campbell,Scott Saxman,Julie A. Kish,Harold Kim,Anthony J. Cmelak,Marvin Rotman,Mitchell Machtay,John F. Ensley,K.S.Clifford Chao,Christopher J. Schultz,Nancy M. Lee,Karen K. Fu +15 more
TL;DR: Among high-risk patients with resected head and neck cancer, concurrent postoperative chemotherapy and radiotherapy significantly improve the rates of local and regional control and disease-free survival, however, the combined treatment is associated with a substantial increase in adverse effects.
Journal ArticleDOI
Postoperative Irradiation With or Without Concomitant Chemotherapy for Locally Advanced Head and Neck Cancer
Jacques Bernier,Christian Domenge,Mahmut Ozsahin,Katarzyna Matuszewska,Jean-Louis Lefebvre,Richard H. Greiner,Jordi Giralt,Philippe Maingon,Frederic Rolland,M. Bolla,Francesco Cognetti,Jean Bourhis,Anne Kirkpatrick,Martine Van Glabbeke +13 more
TL;DR: Postoperative concurrent administration of high-dose cisplatin with radiotherapy is more efficacious than radiotherapy alone in patients with locally advanced head and neck cancer and does not cause an undue number of late complications.